Vertex Pharmaceuticals, which transformed the treatment landscape for cystic fibrosis (CF) by creating medicines that now cover 90% of CF patients, is advancing its mission under the leadership of CEO Reshma Kewalramani. Initially, Vertex developed a drug catering to a mere 4% of CF patients; however, their extensive portfolio now encompasses multiple blockbuster drugs and combinations aimed at addressing the needs of the vast majority of those suffering from this lung condition.
As Vertex approaches its goal of reaching every CF patient, the company’s focus has broadened to include diversification of its pipeline. Due to the substantial revenue generated by its CF treatments, Vertex recognizes the need to expand into new therapeutic areas to sustain growth. This strategy builds upon the insights and experiences gained from their CF research, aiming for repeated and ongoing innovation rather than isolated success.
Speaking at a fireside chat during the World Medical Innovation Forum in Boston, Kewalramani elucidated the company’s aspirations to evolve their innovative endeavors from CF to other diseases. Outside the realm of CF, Vertex began exploring pain medication research even earlier, having started their pain program 25 years ago compared to the 20-year history of their CF research. Recognizing the lack of innovation in treatments for acute and chronic pain, where opioids had become the primary solution, Vertex is advancing a novel approach to pain management that addresses safety, tolerability, and addiction issues prevalent in central nervous system-based opioid treatments.
Their most advanced pain management candidate, Suzetrigine, exemplifies Vertex’s strategy to innovate in pain treatment. This non-opioid molecule works by blocking the NaV1.8 sodium channel found in peripheral nerves, thus preventing pain signals from reaching the brain. Despite competition in sodium channel-blocking drugs, Vertex expects to be a frontrunner, with the FDA having accepted its new drug application and set a regulatory decision date for January 30, 2025. Vertex’s plans in the pain treatment landscape include targeting acute and neuropathic pain, and potentially exploring the musculoskeletal pain market through partnerships.
Furthermore, Vertex has been instrumental in bringing pioneering therapies beyond pain and CF treatments. Thirty-five years ago, Vertex focused primarily on small molecule drugs. Today, it has achieved a milestone by becoming the first to secure FDA approval for a CRISPR-Cas9 therapy called Casgevy, aimed at treating rare blood disorders like sickle cell disease and beta thalassemia.
Vertex is also making strides in type 1 diabetes treatment with its cell therapy programs. One of these, VX-880, involves transforming stem cells into pancreatic islet cells that regulate insulin in response to glucose levels. Addressing immune rejection issues characteristic of such treatments, their next advancement, VX-264, involves encapsulating islet cells within a proprietary device that obviates the need for chronic immunosuppression. Additionally, Vertex is developing a preclinical program using CRISPR technology to edit cells to evade immune responses, potentially shifting from chronic management to curative treatment for type 1 diabetes.
Kewalramani emphasized that Vertex operates on a disease-first approach, employing any necessary modality to potentially transform or cure targeted diseases. This flexible strategy allows the integration of various therapeutic modalities, reinforcing Vertex’s commitment to innovation across different areas of medical need. As Vertex continues to expand its portfolio and explore new therapeutic horizons, its foundational commitment to serial innovation in service of unmet medical needs remains clear.
#Pain #Meds #Cell #Therapies #Vertex #Pharma #CEO #Talks #Whats #Cystic #Fibrosis
